Shares

16 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 14, 2024

BUY
$2.73 - $4.73 $2.52 Million - $4.36 Million
922,214 New
922,214 $2.73 Million
Q4 2023

Feb 09, 2024

BUY
$3.91 - $5.93 $3.61 Million - $5.47 Million
922,214 New
922,214 $5.27 Million
Q3 2023

Nov 13, 2024

BUY
$4.6 - $7.95 $4.24 Million - $7.33 Million
922,214 New
922,214 $4.24 Million
Q3 2023

Nov 13, 2023

SELL
$4.6 - $7.95 $2.4 Million - $4.15 Million
-522,410 Closed
0 $0
Q2 2023

Aug 14, 2024

BUY
$5.66 - $7.59 $3.7 Million - $4.96 Million
653,447 Added 70.86%
1,575,661 $10.2 Million
Q2 2023

Aug 14, 2023

SELL
$5.66 - $7.59 $1.62 Million - $2.17 Million
-285,369 Closed
0 $0
Q1 2023

May 15, 2024

BUY
$7.31 - $11.18 $11.5 Million - $17.6 Million
1,575,661 New
1,575,661 $11.9 Million
Q4 2022

Feb 14, 2023

BUY
$9.48 - $14.52 $6.13 Million - $9.39 Million
646,699 New
646,699 $6.55 Million
Q3 2022

Nov 13, 2023

BUY
$9.2 - $13.68 $4.81 Million - $7.15 Million
522,410 New
522,410 $5.17 Million
Q2 2022

Aug 14, 2023

BUY
$5.72 - $10.65 $1.63 Million - $3.04 Million
285,369 New
285,369 $3.04 Million
Q1 2022

May 12, 2023

SELL
$7.46 - $14.14 $2.7 Million - $5.11 Million
-361,330 Reduced 55.87%
285,369 $2.78 Million
Q1 2022

May 09, 2022

SELL
$7.46 - $14.14 $2.13 Million - $4.04 Million
-285,369 Closed
0 $0
Q4 2021

Mar 09, 2022

BUY
$12.99 - $17.73 $3.71 Million - $5.06 Million
285,369 New
285,369 $4.08 Million
Q3 2021

Nov 14, 2022

BUY
$14.85 - $21.34 $1.78 Million - $2.56 Million
120,194 New
120,194 $2.41 Million
Q3 2021

Nov 05, 2021

SELL
$14.85 - $21.34 $742,500 - $1.07 Million
-50,000 Closed
0 $0
Q2 2021

Aug 15, 2022

BUY
$20.19 - $34.17 $1.01 Million - $1.71 Million
50,000 New
50,000 $1.1 Million

Others Institutions Holding ABCL

About AbCellera Biologics Inc.


  • Ticker ABCL
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 285,139,008
  • Market Cap $787M
  • Description
  • AbCellera Biologics Inc. develops antibody discovery platform. Its full-stack, artificial intelligence-powered antibody discovery platform searches and analyzes the database of natural immune systems to find antibodies that could be developed as drugs. As of December 31, 2021, the company had 156 discovery programs that are either completed, in ...
More about ABCL
Track This Portfolio

Track Norges Bank Portfolio

Follow Norges Bank and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Norges Bank, based on Form 13F filings with the SEC.

News

Stay updated on Norges Bank with notifications on news.